Welcome to our dedicated page for IMPL news (Ticker: IMPL), a resource for investors and traders seeking the latest updates and insights on IMPL stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect IMPL's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of IMPL's position in the market.
Impel NeuroPharma will present a corporate overview at the Raymond James Human Health Innovations Conference on June 23, 2021, at 3:20 p.m. ET. The company is dedicated to developing therapies for central nervous system diseases with high unmet needs. Their pipeline includes products like TRUDHESA™ for migraines and INP105 for autism-related agitation. A live webcast of the presentation will be available on their website, with an archived version accessible shortly after the event.
Impel NeuroPharma (NASDAQ: IMPL) recently completed a successful IPO, raising approximately $80.0 million in gross proceeds. The FDA accepted its NDA for TRUDHESA, aimed at treating acute migraines, with a PDUFA date set for September 6, 2021. The company strengthened its commercial capabilities by expanding its management team and partnering with Veeva Systems. For Q1 2021, Impel reported a net loss of $11.4 million, with R&D expenses decreasing to $4.1 million, while G&A expenses increased to $5.8 million.
Impel NeuroPharma has announced findings from the pivotal STOP-301 study on INP104, a novel treatment for acute migraine attacks, at the 63rd American Headache Society Annual Scientific Meeting. The results highlight INP104's safety, tolerability, and exploratory efficacy, demonstrating a consistent response across multiple migraine attacks and low rates of recurrence. Over 6,000 doses were evaluated, with less than 1% reporting nausea. The FDA is set to review the New Drug Application for INP104, with a decision expected by September 6, 2021.
Impel NeuroPharma (Nasdaq: IMPL) launched Reroute Migraine Relief, an initiative designed to increase awareness of migraines and the brain-gut connection. Featuring artwork by Ed Fairburn, the campaign highlights that 36 million people in the U.S. suffer from migraines, often accompanied by gastrointestinal symptoms. The initiative aims to educate healthcare providers and patients on the complexities of migraine and explore alternative treatment routes, especially utilizing the upper nasal space for medication delivery, which could enhance treatment efficacy.
Impel NeuroPharma, a late-stage pharmaceutical company, has announced its initial public offering (IPO) pricing at $15.00 per share for a total of 5,333,334 shares. The offering, expected to raise $80 million, will trade on Nasdaq under the symbol "IMPL" starting April 23, 2021. The shares are set to close by April 27, 2021, pending customary closing conditions. Additionally, underwriters have a 30-day option to purchase 800,000 extra shares. Proceeds are intended for advancing Impel's CNS therapies, including TRUDHESA for migraine treatment.